Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

MOREPEN LABORATORIES LTD. - 500288 - Shareholding Meeting-Extra-Ordinary General Meeting Scheduled To Be Held On Saturday, March 05, 2022 At 4.00 P.M. (I.S.T.) Through Video Conferencing/ Other Audio Video Means ('VC'/ 'OAVM')

 Pursuant to Regulation 30 read with Part A of Schedule III of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, please find enclosed Notice of the Extra-Ordinary General Meeting ('EGM') of the members of Morepen Laboratories Limited ('the Company'), scheduled to be held on Saturday, 5th March, 2022 at 4.00 p.m. (I.S.T.) through Video Conferencing/ Other Audio Video Means ('VC'/ 'OAVM'), in accordance with the relevant circulars issued by the Ministry of Corporate Affairs and Securities and Exchange Board of India. .
11-02-2022

Morepen Laboratories Q3 Results | Profit dips 10% to Rs 22 crore

 The drug maker had reported a net profit of Rs 23.79 crore in the same period of previous fiscal year.
08-02-2022
Bigul

Q3FY22 Quarterly Result Announced for Morepen Laboratories Ltd.

 Pharmaceuticals company Morepen Laboratories declares Q3FY22 result: Morepen Labs Q3 Revenue up by 29% with 14% jump in Profit before Tax (PBT) 43% increase in API Export Net Revenues for Q3 FY’ 22 at Rs. 399.19 crore were up by 29 per cent against Rs. 310.26 crore of revenues recorded in Q3 revenues FY’21. EBITDA and Cash Profit for Q3 FY’22 went up by 7 per cent and 9 per cent at Rs. 34.81 crore and Rs. 34.07 crore, respectively. Profit before Tax for Q3 FY’ 22 is up by 14 per cent at Rs. 27.14 crore. Net Profit After Tax for Q3 FY’ 22 is down by 10 per cent at Rs. 21.52 crore. Revenue growth for the current quarter was led by API Business, which grew by 41 per cent at Rs. 232.95 crore, followed by OTC and Formulation businesses which grew up by 46 percent and 23 percent respectively. Export Revenues for Q3 FY’22 at Rs. 158.26 crore are up by 41 per cent. Domestic Revenues at Rs. 240.93 crore grew up by 22 per cent. Diagnostic Devices business grew up by 7 per cent at Rs. 93.66 crore in Q3 FY’ 22. Sales of Blood Pressure Monitors was up by 39 per cent, whereas Blood Glucose Monitors revenue grew by 16 per cent. Board approves allotment of Equity Capital of Rs.114.65 crore to Banks/FIIs and others by conversion of Preference Capital Mr. Sushil Suri, Chairman and Managing Director stated, “Business is growing exponentially in all the segments and the company needs to put up additional capacities to serve the customers faster and also capture additional market share. We are working to augment the existing capital base to fund the upcoming growth”. Mr. Suri further added, “The conversion of Bank’s Preference shares, outstanding since many years, into Equity capital is a big milestone and we are thankful to all the Banks for granting their approval. This was the last leg of the CDR process and company will have no outstanding liability in terms of unredeemed preference capital.” Result PDF
08-02-2022
Bigul

MOREPEN LABORATORIES LTD. - 500288 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Please find enclosed the press release with the title - 'Morepen Labs Q3 Revenue up by 29% with 14% jump in Profit before Tax (PBT), 43% increase in API Export'.
08-02-2022
Bigul

MOREPEN LABORATORIES LTD. - 500288 - Announcement under Regulation 30 (LODR)-Investor Presentation

 Please find enclosed the Investors Presentation (Q3'FY22) February 2022, based on the financial performance of the Company for the Quarter and Nine months ended 31st December, 2021.
08-02-2022
Bigul

MOREPEN LABORATORIES LTD. - 500288 - Board Meeting Outcome for Outcome Of Board Meeting

 Pursuant to Regulation 30 of the SEBI Listing Regulations, please find attached outcome of the Board Meeting held today i.e., Tuesday, 8th February 2022 (commenced at 10.30 a.m. and concluded at 11:30 a.m.)
08-02-2022
Bigul

MOREPEN LABORATORIES LTD. - 500288 - Results-Financial Results For The Quarter And Nine-Months Ended 31St December, 2021

 Pursuant to Regulation 30 of the SEBI Listing Regulations, we wish to inform that, the Board of Directors of the company in their meeting held today i.e., Tuesday, 8th February 2022 (commenced at 10.30 a.m. and concluded at 11:30 a.m.), inter-alia, considered and approved: - (1) Un-audited Standalone and Consolidated Financial Results of the Company for the quarter and nine-months ended 31st December, 2021. (2) Variation/alteration of preference shareholders' rights by issue and allotment of 97,35,201, 0.01% Compulsorily Convertible Preference Shares ('CCPS') of Rs. 100/- each in lieu of existing 97,35,201, 0.01% Optionally Convertible Preference Shares ('OCPS') of Rs. 100/- each; and 17,30,000, 0.01% CCPS of Rs. 100/- each in lieu of existing 17,30,000, 0.01% Cumulative Redeemable Preference Shares ('CRPS') of Rs. 100/-.
08-02-2022
Bigul

MOREPEN LABORATORIES LTD. - 500288 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we would like to inform you that subsequent to the declaration of unaudited standalone and consolidated financial results for the quarter and nine months ended 31st December 2021, the Company is organizing an 'Investors and Analyst Conference Call' on Wednesday, 09th February, 2022 at 4.00 P.M. (IST).
07-02-2022
Bigul

MOREPEN LABORATORIES LTD. - 500288 - Shareholding for the Period Ended December 31, 2021

 Morepen Laboratories Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2021. For more details, kindly Click here
21-01-2022
Bigul

MOREPEN LABORATORIES LTD. - 500288 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Pursuant to the Regulation 39(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, please find attached herewith letter dated 19th January, 2022, received from Registrar and Share Transfer Agent (viz., Mas Services Limited) of the company, comprising information related to issue of duplicate share certificate of the company.
20-01-2022
Next Page
Close

Let's Open Free Demat Account